Ihre Erfindung in guten Händen
Industry Technology offers Life Sciences
| Life Sciences |
|
Result 1 - 10 of 48 Technology Offers
A novel method for the preparation of a strain-adapted vaccineVaccinesA method for the preparation of a strain-adapted vaccine specific for a bacterial strain. Combined application of epigenetic modifiers and TALEsOncologyThe patented method enables the reactivation of epigenetically-silenced genes. The scientists have discovered a method for removing methyl groups in certain areas of the DNA, which can be used to reactivate epigenetically-silenced genes. While known transcription factors (proteins that bind to the DNA and switch a gene on via a promoter) like TALEs or zinc fingers already dock at certain gene sections of the DNA, this has not been possible up to now in the case of epigenetically-silenced gene sequences. This problem has now been solved through the addition of valproic acid (VPA 10) and a HDAC inhibitor. This measure made it possible to open the packaging of the epigenetically-silenced gene sequences, which consists of HDAC (histone deacetylases), making them accessible to the transcription factors. LASP-1, a novel Urinary Marker for Bladder Cancer DetectionDiagnosticsOncology
The invention describes the development of a novel urinary marker for the detection of bladder cancer. With an overall sensitivity and specificity of 83.1% and 85.3%, respectively, this marker is superior over commercially available tumor-associated TCC marker. Avoiding of graft rejection and new therapy for autoimmune diseasesImmunology & Inflammation DiseasesBacterial Toxin/IL-2 fusion proteins for the Induction of Antigen-specific Tolerance. New Application for Denileukin Difitox (DAB 389 IL-2; Ontak) Magnetic macromolecules of defined adjustable size and propertiesChemistryDrug Delivery Magnetic particles and molecules have the advantage that their movement and localisation can be controlled by a magnetic field. In an application called Magnetofection, magnetic nanoparticles are, e.g., used deliver cargo such as DNA to cells to improve transfection. The invention describes star-shaped magnetic nanoparticles. These structures are readily taken up by cells including, suspension, primary and blood cells (human T-lymphocytes). No magnetic field is required for cellular uptake. Once inside cells, however, the particles (alone or cargo-loaded) stay magnetically active. Novel BMP2 antagonist inhibitors for bone graft substitutionBiologicalsBiochemical Engineering Medical Technology
Recombinant bone morphogenetic protein 2 (BMP-2) is a known bone graft substitute used in the treatment of bone fractures and bone defects and is currently available on the market. BMP-2 must be applied in high concentrations to induce bone formation in clinical settings. Its limited therapeutic efficacy may be due to the presence of BMP antagonists that neutralize exogenous BMP-2. Inventors at the University of Würzburg (Germany) have identied a novel inactive BMP-2 mutein, named L51P, which acts as an inhibitor of BMP antagonists noggin, chordin and gremlin. In vitro and in vivo validation studies with a combination of BMP-2 and L51P led to a signi cant increase in BMP activity. New explosivesChemistryTwo new high performing secondary explosives, namely ABTOX and TKX50 have been synthesized in excellent yields even in larger quantities. They were completely characterized with respect to their chemical and energetic properties. Both show great performance while being less sensitive than commonly used explosives such as hexogen and octogen. New non-viral transfection agents better than PEIDrug Delivery
The invention describes new PDMAEMA-based vehicles for the highly efficient transport of polynucleotides into cells and also into their nucleus. The new polyelectrolyte particles offer a series of advantages compared to known synthetic non-viral vectors, including the current gold standard poly(ethylene Novel peptide inhibitors for the treatment of malignant melanomaOncologyMalignant melanoma is characterized by aggressive local growth and early formation of metastasis. The Melanoma Inhibitory Activity (MIA) protein is known to promote invasion of melanoma cells into healthy tissue and triggers formation of metastases. After determining the functional state of MIA, the inventors of the University of Regensburg (Germany) have identi ed several peptides which inhibit MIA protein functional activity and strongly reduce the formation of metastases in vivo. These inhibitors may offer a novel treatment strategy in preventing or reducing of formation of metastases in malignant melanoma. New inhibitor of miR-24 for the treatment of ischemiaCardiovascular DiseasesThe invention shows the use of miR-24 modulation to interfere with angiogenic signalling in vitro and in vivo. MiR-24 is triggering endothelial cell (EC) apoptosis via a signal cascade involving the mediators GATA2, PAK4 and others. This is also accompanied by a deficient angiogenic response. MiR-24 antagonism can block these detrimental effects. In a murine model of myocardial infarction (MI) reflecting ischemic disease, miR-24 expression is enhanced specially in cardiac ECs. Following MI, therapeutic intervention with a miR-24 specific antagonist lowered endogenous miR-24, preserved cardiac function and improved capillary density. The same pro-angiogenic effects were seen when implanting matrigel plugs to mice after treatment with miR-24 inhibitors. Thus, therapeutic knockdown of miR-24 is beneficial for cardiac performance upon MI and likely many other ischemic diseases. Collectively, miR-24 modulation can be useful in different settings of ischemic disease to sustain vasculature. As we have investigated therapeutic miR-24 intervention upon MI and in implanted matrigel plugs, we conclude that our results can be transferred to other ischemic stress models like hindlimb ischemia (peripheral occlusive disease), ischemic gut diseases, ischemia of virtually all organs such as kidney, liver, brain, spleen, dermal tissue, lung and others. In addition surgical operations and organ transplantation often result in ischemia-triggered organ function, which could be a target of miR-24 inhibitory therapies. |
Copyright © 2010, Bayerische Patentallianz GmbH, Destouchesstr. 68, 80796 München All Rights Reserved. | Sitemap | Impressum | Datenschutz | Nach oben 